Cardiovascular disease in SARS‐CoV‐2 infection
Abstract Pre‐existing cardiovascular disease (CVD) increases the morbidity and mortality of COVID‐19 and is strongly associated with poor disease outcomes. However, SARS‐CoV‐2 infection can also trigger de novo acute and chronic cardiovascular disease. Acute cardiac complications include arrhythmia,...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Clinical & Translational Immunology |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cti2.1343 |
| _version_ | 1818902231630479360 |
|---|---|
| author | Kei Sato Jane E Sinclair Habib Sadeghirad John F Fraser Kirsty R Short Arutha Kulasinghe |
| author_facet | Kei Sato Jane E Sinclair Habib Sadeghirad John F Fraser Kirsty R Short Arutha Kulasinghe |
| author_sort | Kei Sato |
| collection | DOAJ |
| description | Abstract Pre‐existing cardiovascular disease (CVD) increases the morbidity and mortality of COVID‐19 and is strongly associated with poor disease outcomes. However, SARS‐CoV‐2 infection can also trigger de novo acute and chronic cardiovascular disease. Acute cardiac complications include arrhythmia, myocarditis and heart failure, which are significantly associated with higher in‐hospital mortality. The possible mechanisms by which SARS‐CoV‐2 causes this acute cardiac disease include direct damage caused by viral invasion of cardiomyocytes as well as indirect damage through systemic inflammation. The long‐term cardiac complications associated with COVID‐19 are incompletely characterised and thought to include hypertension, arrhythmia, coronary atherosclerosis and heart failure. Although some cardiac‐related symptoms can last over 6 months, the effect of these complications on long‐term patient health remains unclear. The risk factors associated with long‐term cardiovascular disease remain poorly defined. Determining which patients are most at‐risk of long‐term cardiovascular disease is vital so that targeted follow‐up and patient care can be provided. The aim of this review was to summarise the current evidence of the acute and long‐term cardiovascular consequences of SARS‐CoV‐2 infection and the mechanisms by which SARS‐CoV‐2 may cause cardiovascular disease. |
| first_indexed | 2024-12-19T20:32:22Z |
| format | Article |
| id | doaj.art-08bcd3eee61a484fa0195992647f7507 |
| institution | Directory Open Access Journal |
| issn | 2050-0068 |
| language | English |
| last_indexed | 2024-12-19T20:32:22Z |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical & Translational Immunology |
| spelling | doaj.art-08bcd3eee61a484fa0195992647f75072022-12-21T20:06:38ZengWileyClinical & Translational Immunology2050-00682021-01-01109n/an/a10.1002/cti2.1343Cardiovascular disease in SARS‐CoV‐2 infectionKei Sato0Jane E Sinclair1Habib Sadeghirad2John F Fraser3Kirsty R Short4Arutha Kulasinghe5Critical Care Research Group The Prince Charles Hospital Brisbane QLD AustraliaSchool of Chemistry and Molecular Biosciences The University of Queensland Saint Lucia QLD AustraliaCentre for Genomics and Personalised Health School of Biomedical Sciences Queensland University of Technology Brisbane QLD AustraliaCritical Care Research Group The Prince Charles Hospital Brisbane QLD AustraliaSchool of Chemistry and Molecular Biosciences The University of Queensland Saint Lucia QLD AustraliaFaculty of Medicine University of Queensland Saint Lucia QLD AustraliaAbstract Pre‐existing cardiovascular disease (CVD) increases the morbidity and mortality of COVID‐19 and is strongly associated with poor disease outcomes. However, SARS‐CoV‐2 infection can also trigger de novo acute and chronic cardiovascular disease. Acute cardiac complications include arrhythmia, myocarditis and heart failure, which are significantly associated with higher in‐hospital mortality. The possible mechanisms by which SARS‐CoV‐2 causes this acute cardiac disease include direct damage caused by viral invasion of cardiomyocytes as well as indirect damage through systemic inflammation. The long‐term cardiac complications associated with COVID‐19 are incompletely characterised and thought to include hypertension, arrhythmia, coronary atherosclerosis and heart failure. Although some cardiac‐related symptoms can last over 6 months, the effect of these complications on long‐term patient health remains unclear. The risk factors associated with long‐term cardiovascular disease remain poorly defined. Determining which patients are most at‐risk of long‐term cardiovascular disease is vital so that targeted follow‐up and patient care can be provided. The aim of this review was to summarise the current evidence of the acute and long‐term cardiovascular consequences of SARS‐CoV‐2 infection and the mechanisms by which SARS‐CoV‐2 may cause cardiovascular disease.https://doi.org/10.1002/cti2.1343cardiovascular diseaseCOVID‐19SARS‐CoV‐2 |
| spellingShingle | Kei Sato Jane E Sinclair Habib Sadeghirad John F Fraser Kirsty R Short Arutha Kulasinghe Cardiovascular disease in SARS‐CoV‐2 infection Clinical & Translational Immunology cardiovascular disease COVID‐19 SARS‐CoV‐2 |
| title | Cardiovascular disease in SARS‐CoV‐2 infection |
| title_full | Cardiovascular disease in SARS‐CoV‐2 infection |
| title_fullStr | Cardiovascular disease in SARS‐CoV‐2 infection |
| title_full_unstemmed | Cardiovascular disease in SARS‐CoV‐2 infection |
| title_short | Cardiovascular disease in SARS‐CoV‐2 infection |
| title_sort | cardiovascular disease in sars cov 2 infection |
| topic | cardiovascular disease COVID‐19 SARS‐CoV‐2 |
| url | https://doi.org/10.1002/cti2.1343 |
| work_keys_str_mv | AT keisato cardiovasculardiseaseinsarscov2infection AT janeesinclair cardiovasculardiseaseinsarscov2infection AT habibsadeghirad cardiovasculardiseaseinsarscov2infection AT johnffraser cardiovasculardiseaseinsarscov2infection AT kirstyrshort cardiovasculardiseaseinsarscov2infection AT aruthakulasinghe cardiovasculardiseaseinsarscov2infection |